C
EW icon

CEDRUS’s Edwards Lifesciences EW Stock Holding History

CEDRUS’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,569
Closed -$242K – 142
2023
Q2 		$242K Hold
2,569
– – 0.17% 132
2023
Q1 		$213K Sell
2,569
-225
-8% -$17.7K 0.15% 151
2022
Q4 		$208K Sell
2,794
-196
-7% -$15.1K 0.17% 145
2022
Q3 		$247K Sell
2,990
-58
-2% -$5.58K 0.23% 97
2022
Q2 		$290K Buy
3,048
+199
+7% +$20.6K 0.28% 78
2022
Q1 		$335K Sell
2,849
-79
-3% -$8.86K 0.3% 82
2021
Q4 		$379K Buy
+2,928
New +$342K 0.37% 81

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

CEDRUS's EW Position: Q3 2023 in Review

CEDRUS sold out of Edwards Lifesciences (EW) in Q3 2023, closing a stake of 2,569 shares — an estimated $242K sold.

CEDRUS first reported a position in EW in Q4 2021 and held it in 7 quarters. The position peaked at $379K in Q4 2021. 1,220 funds tracked by Wall St. Rank hold EW as of Q3 2023.

  • CEDRUS reported no remaining Edwards Lifesciences position as of Q3 2023 after selling out during the quarter.
  • CEDRUS sold 2,569 Edwards Lifesciences shares in Q3 2023, an estimated $242K.
  • CEDRUS first reported a position in Edwards Lifesciences in Q4 2021 and held it in 7 quarters.
  • CEDRUS's Edwards Lifesciences position peaked at $379K in Q4 2021.
  • 1,220 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2023.

Based on CEDRUS's 13F filing for Q3 2023, filed 24 Jan 2024.